MRK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Merck's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.38.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Merck couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.
The historical rank and industry rank for Merck's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Merck's highest Cash to Debt Ratio was 0.73. The lowest was 0.16. And the median was 0.35.
The historical data trend for Merck's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Merck Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash-to-Debt | Get a 7-Day Free Trial | 0.40 | 0.25 | 0.25 | 0.43 | 0.20 |
Merck Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cash-to-Debt | Get a 7-Day Free Trial | 0.25 | 0.20 | 0.16 | 0.30 | 0.38 |
For the Drug Manufacturers - General subindustry, Merck's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Merck's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Merck's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Merck's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 7093 | / | (1372 | + | 33683) | |
= | 0.20 |
Merck's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 14593 | / | (3149 | + | 34982) | |
= | 0.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (NYSE:MRK) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Merck's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert M Davis | officer: Evp, Global Svcs & CFO | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Caroline Litchfield | officer: EVP & CFO | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Joseph Romanelli | officer: President, Human Health Int?l | 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065 |
Dean Y Li | officer: Executive VP & President, MRL | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
David Michael Williams | officer: EVP,Chief Info&Digital Officer | MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Johannes Jacobus Oosthuizen | officer: SVP, U.S. Market | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Richard R. Deluca | officer: EVP&Pres, Merck Animal Heallth | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Steven Mizell | officer: EVP,Human Resources | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Rita A Karachun | officer: Sr. VP Fince-Global Controller | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Jennifer Zachary | officer: EVP, General Counsel | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Sanat Chattopadhyay | officer: Exe V-P & Pres. MMD | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Kenneth C Frazier | officer: Chairman, President & CEO | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Chirfi Guindo | officer: Chief Marketing Officer | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Baker Douglas M Jr | director | 370 WBASHA ST NORTH, ST PAUL MN 55102 |
Arpa Garay | officer: SVP Human Health Global Mktg. | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
From GuruFocus
By GuruFocus News • 11-21-2024
By GuruFocus News • 11-26-2024
By GuruFocus News • 12-05-2024
By Business Wire • 11-19-2024
By GuruFocus News • 11-20-2024
By Business Wire • 11-22-2024
By Business Wire • 11-06-2024
By Business Wire • 11-12-2024
By Faizan Farooque • 12-03-2024
By GuruFocus News • 11-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.